Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 1;5(2):e2148355.
doi: 10.1001/jamanetworkopen.2021.48355.

Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease

Julie Zissimopoulos  1   2 , Mireille Jacobson  2   3 , Yi Chen  2   4 , Soo Borson  5
Affiliations

Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease

Julie Zissimopoulos et al. JAMA Netw Open. .

Abstract

This survey study examines the understanding of aducanumab and attitudes toward its potential outcomes among older Americans after the drug's approval by the US Food and Drug Administration (FDA) for the treatment for Alzheimer disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Borson reported serving as an author of an information sheet prepared by the American Geriatrics Society for consumers and patients regarding aducanumab. No other disclosures were reported.

Figures

Figure.
Figure.. Odds of Agreement With Statements About Aducanumab
Odds ratios (ORs) and 95% CIs for agreeing with the statements “increases chances will seek screening” and “would want to receive Aduhelm (aducanumab) if had Alzheimer disease” are shown in A and B, respectively. ORs were obtained from multivariate logistic regressions adjusting for sex, age group, race and ethnicity, and education. Ages 55 to 59 years is the reference group for other age groups, and less than high school is the reference group for other education groups. The reference group for non-Hispanic White individuals was members of other race and ethnicity groups, which included African American, Asian American, American Indian or Alaska Native, Hispanic or Latino, and Native Hawaiian or other Pacific Islander individuals and individuals reporting 2 or more races. The sample included 977 individuals who saw and answered question A and 1033 individuals who saw and answered question B.
See this image and copyright information in PMC

Comment in

References

    1. Belluck, P. F.D.A. panel declines to endorse controversial Alzheimer’s drug. New York Times. Accessed September 17, 2021. https://www.nytimes.com/2020/11/06/health/aducanumab-alzheimers-drug-fda...
    1. Hollmann P, Lundebjerg NE. Re: Food and Drug Administration’s review of Biogen’s drug aducanumab for Alzheimer’s disease. American Geriatrics Society. Accessed September 17, 2021. https://www.americangeriatrics.org/sites/default/files/inline-files/Amer...
    1. Alzheimer's Association . Alzheimer's Association welcomes FDA approval of aducanumab. Accessed September 17, 2021. https://www.alz.org/news/2021/alzheimers-association-fda-approval-aducan...
    1. Crosson FJ, Covinsky K, Redberg RF. Medicare and the shocking US Food and Drug administration approval of aducanumab: crisis or opportunity? JAMA Intern Med. 2021;181(10):1278-1280. doi:10.1001/jamainternmed.2021.4610 - DOI - PubMed
    1. Alattar L, Messel M, Rogofsky S.. An introduction to the Understanding America Study internet panel. Soc Secur Bull. 2018; 78(2).

Publication types

MeSH terms

Substances